Patent ID: 7803546
Filing Date: 2010-09-28
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A method of screening an individual with prostate or lung cancer for sensitivity to gefitinib therapy, comprising: obtaining a tumor sample from the individual with prostate or lung cancer; contacting the tumor sample with a nucleic acid probe for epithelial membrane protein 1 (EMP-1); examining an expression level of EMP-1 mRNA the tumor sample; caring the expression level of EMP-1 mRNA of the tumor sample to an expression level of EMP-1 mRNA of a gefitinib sensitive prostate or lung tumor; and determining the prostate or lung cancer is resistant or non-responsive to conventional gefitinib therapy when the expression level of EMP-1 mRNA of the tumor sample is 20-fold or higher than the expression level of EMP-1 mRNA of the gefitinib sensitive prostate or lung tumor.